https://orcid.org/0000-0002-3147-5688
Figures & data
Figure 1 Patient screening algorithm for Flu-p.
Notes: A total of 3405 patients positive for influenza viral RNA were screened, and 1191 eligible Flu-p patients were recruited in this study.
Table 1 Comparison of Clinical Features and Outcomes Between Patients with and without CVEs
Figure 2 Frequency and type of CVEs occurred in Flu-p patients.
Notes: At least one type of CVE occurred in 24.6% of Flu-p patients, with the most common CVEs being arrhythmia (17.4%), heart failure (15.5%), myocardial infarction (4.6%), stroke (4.2%), and pulmonary embolism (1.0%).
Figure 3 Timing of CVEs in Flu-p patients.
Notes: The median times between admission and the incidence of each CVE type were as follows: arrhythmia (2.0 days, IQR: 1.0–5.0 days), heart failure (3.0 days, IQR:2.0–4.0 days), MI (2.0 days, IQR: 1.0–3.0 days), stroke (7.0 days, 5.0–8.0 days), and PE (11.5 days, IQR: 10.0–14.0 days).
Figure 4 Risk factors for the incidence of CVEs in Flu-p patients.
Notes: Multivariate logistic regression analysis revealed that hypertension, coronary artery disease, chronic heart failure, cerebrovascular disease, respiratory rate ≥ 30 breaths/min, systolic blood pressure < 90 mmHg, lymphocytes < 0.8×109/L, PaO2/FiO2 < 300 mmHg at admission, and systemic corticosteroid administration were associated with an increased risk of CVEs, while early NAI administration and ACEIs/ARBs treatment were related to a decreased risk of CVEs.
Table 2 The Impact of CVEs on the 30-Day Mortality of Flu-p Patients
Figure 5 The impact of CVEs numbers on the 30-day mortality of Flu-p patients.
Notes: Relative to patients that did not experience CVEs, the survival rates of patients that experienced one, two, or three types of CVEs within 30 days following admission were significantly lower.
